Loading...
OTCM
KOAN
Market cap117kUSD
Jul 09, Last price  
0.00USD
1D
0.00%
1Q
-66.67%
Jan 2017
-45.45%
Name

Resonate Blends Inc

Chart & Performance

D1W1MN
OTCM:KOAN chart
P/E
P/S
0.07
EPS
Div Yield, %
Shrs. gr., 5y
51.85%
Rev. gr., 5y
12.55%
Revenues
2m
-10.17%
8,501,00014,404,00011,904,0007,400,0003,224,0002,694,000246,224339,533342,252317,468458,271943,7391,066,4081,050,161027,03149,50116,4681,896,2151,703,326
Net income
-2m
L-18.79%
-1,220,0003,025,000-775,000-4,638,000-1,708,000172,000-25,460-111,947-456,453-3,554,512-3,262,051-7,649,22021,003-3,880,643-2,052,283-5,019,6212,868,377-1,415,979-2,133,208-1,732,286
CFO
-2m
L+47.56%
643,0004,463,0001,047,000-781,000-926,000715,000-11,155-54,696-149,200-381,472-433,282-145,719-101,803-809,386-1,381,003-2,792,687-1,428,46711,166-1,029,062-1,518,510
Dividend
Apr 10, 19960.02 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

APOLLO BioWellness Inc. focuses its efforts on researching, formulating, and bringing to market products designed for human health within the regenerative medicine sector. A significant part of its operations involves the commercialization of licensed, naturally derived compounds currently awaiting patent approval, which are specifically engineered to boost an individual's innate capacity to mobilize adult stem cells from their own bone marrow. Additionally, the firm possesses the marketing rights for an all-natural, two-pronged dietary supplement crafted to help regulate hunger by engaging the body's intrinsic signaling pathways between the brain and the digestive system. Beyond its current offerings, the company is also deeply involved in research and development initiatives. These efforts are dedicated to exploring new frontiers, such as Secretogues aimed at enhancing a person's endogenous growth hormone synthesis, along with other natural bioactive formulations intended to optimize human physiological performance. This is achieved by harnessing the body's own biological mechanisms, entirely without the use of pharmaceutical drugs. The company maintains its corporate headquarters in North Bergen, New Jersey.
IPO date
Mar 31, 1993
Employees
6
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT